Patient-Derived Xenograft Model Market Size, Share | Report 2022-2030
The global patient-derived xenograft model market was surpassed at USD 140.3 million in 2021 and is expected to hit around USD 552.48 million by 2030, growing at a CAGR of 16.45% from 2022 to 2030.
Report Summary
The global patient-derived xenograft model market is anticipated to reflect a considerable growth rate across the forecast period. Some of the major factors driving the patient-derived xenograft model market include the rise in the number of researches globally, growing burden of cancer, promoting the demand for new treatment options; and significant demand for personalized therapies worldwide.
PDX models have certain advantages, such as the ability to partially recapitulate the tumor microenvironment. These models maintain genetic and histologic features of origin, have high predictive value and also can be used as a metastatic model. These factors of the PDX model further support the growth of the patient-derived xenograft model market.
Public organizations globally are taking initiatives to improve research activities globally. For instance, in August 2022, the NIH provided the SBIR grant to AVM Biotechnology to conduct research on the effect of drugs on lymphoma. Similar initiatives by public organizations in the future are expected to promote the market's growth to a great extent.
During the COVD-19 pandemic, cancer research was halted as the majority of studies were focused on developing drugs for COVID-19. However, in the post-pandemic period, the majority of the focus of researchers is on developing innovative therapies for cancer. This is expected to support the growth of the patient-derived xenograft model market in the post-pandemic period.
Based on end-user, the pharmaceutical and biopharmaceutical companies segment held a substantial share in the market. The growing number of research projects by these companies in the areas of personalized medicine and cancer are the key factors contributing to the growth of the segment market.
North America held a significant share in the market in 2021. The growing number of research studies in the region, significant number of funding for preclinical researches and growing demand for innovative therapies are some of the key factors driving the patient-derived xenograft model market in North America. The surge in the cancer burden in the region further supports the growth of the North America patient-derived xenograft model market.
Scope of The Report
| Report Coverage | Details |
| Market Size in 2021 | USD 140.3 million |
| Revenue Forecast by 2030 | USD 552.48 million |
| Growth rate from 2022 to 2030 | CAGR of 16.45% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segmentation | Tumor Type, Application, End User, Region |
| Companies Covered |
Charles River Laboratories; THE JACKSON LABORATORY; Crown Bioscience.; Altogen Labs; Envigo; WuXi AppTec; Oncodesign; Hera Biolabs; XenTech; and Abnova Corporation. |
Key Players
Market Segmentation
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Patient-Derived Xenograft Model Market
5.1. COVID-19 Landscape: Patient-Derived Xenograft Model Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Patient-Derived Xenograft Model Market, By Tumor Type
8.1. Patient-Derived Xenograft Model Market, by Tumor Type, 2022-2030
8.1.1 Lung Cancer
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Pancreatic Cancer
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Prostrate Cancer
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Breast Cancer
8.1.4.1. Market Revenue and Forecast (2017-2030)
8.1.5. Other Cancer
8.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Patient-Derived Xenograft Model Market, By Application
9.1. Patient-Derived Xenograft Model Market, by Application, 2022-2030
9.1.1. Preclinical Studies
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Biomarker Analysis
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Cancer Research
9.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Patient-Derived Xenograft Model Market, By End User
10.1. Patient-Derived Xenograft Model Market, by End User, 2022-2030
10.1.1. Pharmaceutical and Biopharmaceutical Comapnies
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Accademic and Research Institutes
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. CRO’s and CDMO’s
10.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Patient-Derived Xenograft Model Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Tumor Type (2017-2030)
11.1.2. Market Revenue and Forecast, by Application (2017-2030)
11.1.3. Market Revenue and Forecast, by End User (2017-2030)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Tumor Type (2017-2030)
11.1.4.2. Market Revenue and Forecast, by Application (2017-2030)
11.1.4.3. Market Revenue and Forecast, by End User (2017-2030)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Tumor Type (2017-2030)
11.1.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.1.5.3. Market Revenue and Forecast, by End User (2017-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Tumor Type (2017-2030)
11.2.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.3. Market Revenue and Forecast, by End User (2017-2030)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Tumor Type (2017-2030)
11.2.4.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.4.3. Market Revenue and Forecast, by End User (2017-2030)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Tumor Type (2017-2030)
11.2.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.5.3. Market Revenue and Forecast, by End User (2017-2030)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Tumor Type (2017-2030)
11.2.6.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.6.3. Market Revenue and Forecast, by End User (2017-2030)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Tumor Type (2017-2030)
11.2.7.2. Market Revenue and Forecast, by Application (2017-2030)
11.2.7.3. Market Revenue and Forecast, by End User (2017-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Tumor Type (2017-2030)
11.3.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.3. Market Revenue and Forecast, by End User (2017-2030)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Tumor Type (2017-2030)
11.3.4.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.4.3. Market Revenue and Forecast, by End User (2017-2030)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Tumor Type (2017-2030)
11.3.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.5.3. Market Revenue and Forecast, by End User (2017-2030)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Tumor Type (2017-2030)
11.3.6.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.6.3. Market Revenue and Forecast, by End User (2017-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Tumor Type (2017-2030)
11.3.7.2. Market Revenue and Forecast, by Application (2017-2030)
11.3.7.3. Market Revenue and Forecast, by End User (2017-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Tumor Type (2017-2030)
11.4.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.3. Market Revenue and Forecast, by End User (2017-2030)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Tumor Type (2017-2030)
11.4.4.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.4.3. Market Revenue and Forecast, by End User (2017-2030)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Tumor Type (2017-2030)
11.4.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.5.3. Market Revenue and Forecast, by End User (2017-2030)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Tumor Type (2017-2030)
11.4.6.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.6.3. Market Revenue and Forecast, by End User (2017-2030)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Tumor Type (2017-2030)
11.4.7.2. Market Revenue and Forecast, by Application (2017-2030)
11.4.7.3. Market Revenue and Forecast, by End User (2017-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Tumor Type (2017-2030)
11.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.5.3. Market Revenue and Forecast, by End User (2017-2030)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Tumor Type (2017-2030)
11.5.4.2. Market Revenue and Forecast, by Application (2017-2030)
11.5.4.3. Market Revenue and Forecast, by End User (2017-2030)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Tumor Type (2017-2030)
11.5.5.2. Market Revenue and Forecast, by Application (2017-2030)
11.5.5.3. Market Revenue and Forecast, by End User (2017-2030)
Chapter 12. Company Profiles
12.1. Charles River Laboratories
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. THE JACKSON LABORATORY
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Crown Bioscience.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Altogen Labs
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Envigo
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. WuXi AppTec
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Oncodesign
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Hera Biolabs
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. XenTec
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Abnova Corporation.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers